Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Status:
Completed
Trial end date:
2008-06-30
Target enrollment:
Participant gender:
Summary
This phase 1/2a trial is conducted in Europe. The first part of the trial is a dose
escalation safety trial determining the maximum tolerated dose of rIL-21 when administered in
combination with sunitinib.
The second part, scheduled to start in September 2008, is a randomised 2-arm trial comparing
the anti-tumour effect of rIL-21 plus sunitinib with sunitinib alone.